Agregex(Clopidogrel Actavis)
Clopidogrelum
Agregex and Clopidogrel Actavis are different trade names for the same medicine.
Agregex contains clopidogrel and belongs to a group of medicines called antiplatelet medicines.
Platelets are very small blood cells that clump together during blood clotting.
By preventing this clumping, antiplatelet medicines reduce the chance of blood clots (a process called thrombosis).
Agregex is used in adult patients to prevent blood clots (thrombi) in hardened blood vessels (arteries) due to atherosclerosis, which can lead to events such as stroke, heart attack, or death.
The patient has been prescribed Aggregex to prevent blood clots and reduce the risk of these serious events, because:
If the patient thinks they may have any of these problems or has any other doubts, they should consult their doctor before taking Aggregex.
Before starting treatment with Aggregex, the patient should discuss it with their doctor or pharmacist.
While taking Aggregex:
The doctor may order blood tests.
This medicine should not be used in children, as it has not been shown to be effective in this group of patients.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken.
Some other medicines may affect the action of Aggregex or vice versa.
In particular, the patient should inform their doctor if they are taking medicines such as:
In patients who have had severe chest pain (unstable angina or heart attack), Aggregex may be prescribed with acetylsalicylic acid, a substance found in many medicines, used to relieve pain and reduce fever.
Occasional use of acetylsalicylic acid (no more than 1000 mg in 24 hours) should not usually cause a problem, but long-term use in other circumstances should be discussed with the doctor.
Agregex can be taken with or without food.
This medicine should not be used during pregnancy and breastfeeding.
If the patient is pregnant, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
If the patient becomes pregnant while taking Aggregex, they should immediately consult their doctor, as clopidogrel is not recommended during pregnancy.
The patient should not breastfeed while taking this medicine.
If the patient is breastfeeding or plans to breastfeed, they should talk to their doctor before taking this medicine.
Before taking any medicine, the patient should consult their doctor or pharmacist.
Agregex contains lactose.If the patient has been diagnosed with an intolerance to some sugars, they should contact their doctor before taking this medicine.
Agregex contains soya lecithin (soybean oil) (E 322). The patient should not take this medicine if they are allergic to peanuts or soy.
The patient should always take this medicine exactly as their doctor or pharmacist has told them. If they are not sure, they should ask their doctor or pharmacist.
The recommended dose, including patients with a condition known as "atrial fibrillation" (irregular heartbeat), is one Aggregex tablet, 75 mg per day, taken orally with or without food, at the same time every day.
If the patient has had severe chest pain (unstable angina or heart attack), their doctor may prescribe a single dose of 300 mg (4 tablets of 75 mg) to start treatment. Then, the recommended dose of Aggregex is one tablet of 75 mg per day, taken as described above.
If the patient has had symptoms of a stroke that have resolved quickly (also known as a transient ischemic attack) or a mild stroke, the doctor may prescribe a single dose of 300 mg of Aggregex (4 tablets of 75 mg) at the start of treatment. Then, the recommended dose is one tablet of Aggregex 75 mg per day, as described above, with acetylsalicylic acid for 3 weeks. Then, the doctor may prescribe Aggregex or acetylsalicylic acid separately.
The patient should take Aggregex for as long as their doctor recommends.
The patient should contact their doctor or the emergency department of the nearest hospital due to an increased risk of bleeding.
If the patient forgets to take a dose of Aggregex but remembers within 12 hours, they should take the tablet immediately and then take the next tablet at the usual time.
If the patient forgets for more than 12 hours, they should simply take the next single dose at the usual time. The patient should not take a double dose to make up for the missed dose.
On packs of 28 tablets, the patient can check the day they last took a tablet of Aggregex in the calendar printed on the blister pack (see "Translation of the day of the week symbols on the packaging" at the end of the leaflet).
The patient should not stop treatment unless their doctor tells them to. Before stopping treatment, the patient should consult their doctor or pharmacist.
If the patient has any further questions about the use of this medicine, they should ask their doctor or pharmacist.
Like all medicines, Aggregex can cause side effects, although not everybody gets them.
bleeding.
Bleeding may occur as stomach or intestinal bleeding, bruising, hematomas (unusual bleeding or bruising under the skin), nosebleeds, blood in the urine. There have also been reports of a small number of cases of bleeding in the eye, into the brain, lungs, or joints.
In case of a cut or injury, the time it takes for the bleeding to stop may be slightly longer than usual. This is related to the way the medicine works, as it prevents blood clots from forming. This usually does not cause problems with minor cuts and injuries, e.g., cuts while shaving. However, if bleeding occurs, the patient should immediately contact their doctor (see section 2 "Warnings and precautions").
Common (may affect up to 1 in 10 people):
Diarrhea, abdominal pain, indigestion, or heartburn.
Uncommon (may affect up to 1 in 100 people):
Headache, stomach ulcer, vomiting, nausea, constipation, excess gas in the stomach or intestines, rashes, itching, dizziness, tingling or numbness.
Rare (may affect up to 1 in 1,000 people):
Vertigo of labyrinthine origin, breast enlargement in men.
Very rare (may affect up to 1 in 10,000 people):
Jaundice, severe abdominal pain with or without back pain, fever, difficulty breathing, sometimes accompanied by coughing, generalized allergic reactions (e.g., feeling of heat with sudden general discomfort up to fainting), swelling of the mouth, blisters, skin allergy, oral discomfort (stomatitis), low blood pressure, disorientation, hallucinations, joint pain, muscle pain, taste disturbances or loss of taste.
Frequency not known (frequency cannot be estimated from the available data):
Hypersensitivity reactions with chest pain or abdominal pain, persistent symptoms of low blood sugar.
The doctor may also detect changes in blood or urine test results.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the National Institute of Pharmacy and Nutrition, 1051 Budapest, Zrínyi u. 3., Tel: +36 1 888 6792, Fax: +36 1 888 6791, email: [melbourne@ogyei.gov.hu](mailto:melbourne@ogyei.gov.hu). By reporting side effects, the patient can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
PVC/PE/PVDC/Aluminum blisters: Do not store above 25°C.
Aluminum/Aluminum blisters: Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer need. This will help protect the environment.
Film-coated tablet.
Pink, round, biconvex film-coated tablet with a diameter of 9 mm, with "I" embossed on one side.
Pack sizes:
PVC/PE/PVDC/Aluminum blisters in a carton: 28 tablets.
Aluminum/Aluminum blisters in a carton: 28 tablets.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Actavis Group PTC ehf
Dalshraun 1
220 Hafnarfjordur
Iceland
Actavis Ltd
BLB015-016, Bulebel Industrial Estate
Zejtun ZTN 3000
Malta
Actavis Group PTC ehf.
Dalshraun 1
220 Hafnarfjordur
Iceland
Balkanpharma-Dupnitsa AD
3 Samakovsko Shosse Str.
Dupnitsa, 2600
Bulgaria
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
CEFEA Sp. z o.o. Sp. komandytowa
ul. Działkowa 56
02-234 Warszawa
Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warszawa
Synoptis Industrial Sp. z o.o.
ul. Szosa Bydgoska 58
87-100 Toruń
IVA Pharm Sp. z o.o.
ul. Drawska 14/1
02-202 Warszawa
CANPOLAND SPÓŁKA AKCYJNA
ul. Beskidzka 190
91-610 Łódź
Marketing authorization number in Hungary, in the country of export: OGYI-T-21097/03
OGYI-T-21097/04
Parallel import authorization number: 94/21
Translation of the day of the week symbols on the packaging:
H
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.